Found: 6
Select item for more details and to access through your institution.
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-42635-2
- By:
- Publication type:
- Article
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 203, n. 3, p. 497, doi. 10.1007/s10549-023-07159-9
- By:
- Publication type:
- Article
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2022, v. 114, n. 12, p. 1720, doi. 10.1093/jnci/djac126
- By:
- Publication type:
- Article
End-of-neoadjuvant treatment circulating microRNAs and HER2- positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.1028825
- By:
- Publication type:
- Article
What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 2, p. 332, doi. 10.1002/cam4.4449
- By:
- Publication type:
- Article
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00452-8
- By:
- Publication type:
- Article